With a closer look at genomic variation, scientists now have a faster, more precise way to uncover new links to disease EMBL ...
Saguaro Biosciences, a pioneer in non-toxic live cell reagents for enhanced drug insights, announces a new distribution agreement with Bio-Techne Corporation (NASDAQ:TECH), a global provider of life ...
EPFL researchers uncover how transcription factor dosage reshapes cell identity, showing that even small differences in dose ...
Indian Defence Review on MSN
Scientists Say They Might Finally Decode Einstein’s Brain—Here’s the Tech That Could Do It
A novel RNA-mapping method could offer unprecedented access to the microscopic structures of some of the most brilliant minds ...
News-Medical.Net on MSN
Researchers develop AI system to decode the human immune system
Researchers explore the human immune system by looking at the active components, namely the various genes and cells involved.
An NIH-supported initiative seeks to unravel how the nervous system tracks and regulates the body’s internal organs. How does ...
The project uses Long-Read Whole Genome Sequencing, one of the world's most advanced DNA sequencing methods, to determine if a child is at risk for serious genetic diseases. Once the data is collected ...
Scientists report the first therapy to slow the deadly brain disease. A one-time gene therapy treatment has shown remarkable success in slowing the progression of Huntington's disease in a preliminary ...
Researchers at Tel Aviv University say they have found an innovative gene therapy method to treat impairments in hearing and balance caused by inner ear dysfunction, providing hope for a cure to ...
A new gene therapy has slowed the progression of Huntington's disease by as much as 75%. Known as AMT-130, it is delivered via brain surgery, and a single dose is expected to last someone's whole life ...
An experimental gene therapy has become the first treatment to successfully slow the progression of Huntington’s disease. While the findings are still preliminary, the approach could be a major ...
The first participant in an investigational gene therapy trial of STXBP1 encephalopathy died, Capsida Biotherapeutics said. The death occurred days after dosing, according to information posted on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback